Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A. Kozarek, Asma Siddique
Clin Mol Hepatol. 2017;23(4):316-322.   Published online 2017 Aug 22     DOI: https://doi.org/10.3350/cmh.2016.0087
Citations to this article as recorded by Crossref logo
Sofosbuvir
Reactions Weekly.2018; 1688(1): 219.     CrossRef
Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic
Jessica L. Michal, Saira Rab, Manish Patel, Alison W. Kyle, Lesley S. Miller, Kirk A. Easley, Aley G. Kalapila
AIDS Research and Human Retroviruses.2018; 34(8): 690.     CrossRef
Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: A Brazilian “real-life” study
T. Medeiros, N. F. Rosário, G. N. Saraiva, T. G. Andrade, A. A. Silva, J. R. Almeida
Journal of Clinical Pharmacy and Therapeutics.2018; 43(5): 707.     CrossRef
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
Clinical and Molecular Hepatology.2018; 24(3): 169.     CrossRef
Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
Chih-Chin Kao, Yu-Shiuan Lin, Heng-Cheng Chu, Te-Chao Fang, Mai-Szu Wu, Yi-No Kang
Journal of Clinical Medicine.2018; 7(10): 314.     CrossRef
Treating hepatitis C virus in dialysis patients: How, when, and why?
Javier Pagan, Marco Ladino, David Roth
Seminars in Dialysis.2018;[Epub]     CrossRef
Use of sofosbuvir in chronic kidney disease: Is it necessary?
Tae Seop Lim, Sang Hoon Ahn
Clinical and Molecular Hepatology.2017; 23(4): 308.     CrossRef